Bazarbachi, A.-H., & Mapara, M. Y. (2024). Cytokines in hematopoietic cell transplantation and related cellular therapies. Best Practice & Research Clinical Haematology, 37(4), 101600. https://doi.org/10.1016/j.beha.2025.101600

Rios, C. A. O., Qayed, M., Etra, A. M., Reshef, R., Newcomb, R., Yuhasz, N., Hexner, E. O., Aguayo-Hiraldo, P., Merli, P., Hogan, W. J., Weber, D., Kitko, C. L., Ayuk, F., Eder, M., Grupp, S. A., Kraus, S., Sandhu, K., Ullrich, E., Vasova, I., … Akahoshi, Y. (2024). Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients. Transplantation and Cellular Therapy, 30(11), 1061.e1-1061.e10. https://doi.org/10.1016/j.jtct.2024.08.019

DeFilipp, Z., Kim, H. T., Spyrou, N., Katsivelos, N., Kowalyk, S., Eng, G., Kasikis, S., Beheshti, R., Baez, J., Akahoshi, Y., Ayuk, F., Choe, H., Etra, A., Grupp, S. A., Hexner, E. O., Hogan, W. J., Kitko, C. L., Qayed, M., Reshef, R., … Chen, Y.-B. (2024). The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD. Blood Advances, 8(13), 3488–3496. https://doi.org/10.1182/bloodadvances.2024012561

Etra, A., El Jurdi, N., Katsivelos, N., Kwon, D., Gergoudis, S., Morales, G., Spyrou, N., Kowalyk, S., Aguayo-Hiraldo, P., Akahoshi, Y., Ayuk, F., Baez, J., Betts, B. C., Chanswangphuwana, C., Chen, Y.-B., Choe, H., DeFilipp, Z., Gleich, S., Hexner, E., … Holtan, S. (2024). Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD. Blood Advances, 8(12), 3284–3292. https://doi.org/10.1182/bloodadvances.2023011049

Mata, J. R., Zahurak, M., Rosen, N., DeZern, A. E., Jones, R. J., & Ambinder, A. J. (2024). Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy, 30(6), 588–596. https://doi.org/10.1016/j.jtct.2024.03.018

Akahoshi, Y., Spyrou, N., Hoepting, M., Aguayo-Hiraldo, P., Ayuk, F., Chanswangphuwana, C., Choe, H. K., Eder, M., Etra, A. M., Grupp, S. A., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kraus, S., Al Malki, M. M., Merli, P., Qayed, M., Reshef, R., Schechter, T., … Nakamura, R. (2024). Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. Blood Advances, 8(8), 2047–2057. https://doi.org/10.1182/bloodadvances.2023012091

Spyrou, N., Akahoshi, Y., Kowalyk, S., Morales, G., Beheshti, R., Aguayo-Hiraldo, P., Al Malki, M. M., Ayuk, F., Bader, P., Baez, J., Capellini, A., Choe, H., DeFilipp, Z., Eder, M., Eng, G., Etra, A., Gleich, S., Grupp, S. A., Hexner, E., … Ferrara, J. L. M. (2024). A Day 14 Endpoint for Acute GVHD Clinical Trials. Transplantation and Cellular Therapy, 30(4), 421–432. https://doi.org/10.1016/j.jtct.2024.01.079

Wang, Y., He, S., Calendo, G., Bui, T., Tian, Y., Lee, C. Y., Zhou, Y., Zhao, X., Abraham, C., Mo, W., Chen, M., Sanders-Braggs, R., Madzo, J., Issa, J.-P., Hexner, E. O., Wiest, D. L., Reshef, R., Xue, H.-H., & Zhang, Y. (2024). Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD. Blood, 143(2), 166–177. https://doi.org/10.1182/blood.2023021126

McCarthy, P. L., Attwood, K. M., Liu, X., Chen, G. L., Minderman, H., Alousi, A., Bashey, A., Lowsky, R., Miklos, D. B., Hansen, J., Westervelt, P., Yanik, G., Waller, E. K., Howard, A., Blazar, B. R., Wallace, P. K., Reshef, R., Horowitz, M. M., Maziarz, R. T., … Mohammadpour, H. (2023). Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplantation, 59(3), 334–343. https://doi.org/10.1038/s41409-023-02168-0

Leiding, J. W., Arnold, D. E., Parikh, S., Logan, B., Marsh, R. A., Griffith, L. M., Wu, R., Kidd, S., Mallhi, K., Chellapandian, D., Si Lim, S. J., Grunebaum, E., Falcone, E. L., Murguia-Favela, L., Grossman, D., Prasad, V. K., Heimall, J. R., Touzot, F., Burroughs, L. M., … Kang, E. M. (2023). Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood, 142(24), 2105–2118. https://doi.org/10.1182/blood.2022019586

Spyrou, N., Akahoshi, Y., Ayuk, F., Holler, E., Choe, H., Etra, A., Hogan, W. J., Rösler, W., Hexner, E., DeFilipp, Z., Reshef, R., Chanswangphuwana, C., Qayed, M., Kraus, S., Eder, M., Javorniczky, N. R., Grupp, S. A., Kitko, C. L., Merli, P., … Ferrara, J. L. M. (2023). The utility of biomarkers in acute GVHD prognostication. Blood Advances, 7(17), 5152–5155. https://doi.org/10.1182/bloodadvances.2023009929

Al Malki, M. M., London, K., Baez, J., Akahoshi, Y., Hogan, W. J., Etra, A., Choe, H., Hexner, E., Langston, A., Abhyankar, S., Ponce, D. M., DeFilipp, Z., Kitko, C. L., Adekola, K., Reshef, R., Ayuk, F., Capellini, A., Chanswangphuwana, C., Eder, M., … Levine, J. E. (2023). Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood Advances, 7(17), 5189–5198. https://doi.org/10.1182/bloodadvances.2023009853

Zhai, N., Liu, W., Jin, C.-H., Ding, Y., Sun, L., Zhang, D., Wang, Z., Tang, Y., Zhao, W., LeGuern, C., Mapara, M. Y., Wang, H., & Yang, Y.-G. (2023). Lack of IFN-γ Receptor Signaling Inhibits Graft-versus-Host Disease by Potentiating Regulatory T Cell Expansion and Conversion. The Journal of Immunology, 211(5), 885–894. https://doi.org/10.4049/jimmunol.2200411

Akahoshi, Y., Spyrou, N., Hogan, W. J., Ayuk, F., DeFilipp, Z., Weber, D., Choe, H. K., Hexner, E. O., Rösler, W., Etra, A. M., Sandhu, K., Yanik, G. A., Chanswangphuwana, C., Kitko, C. L., Reshef, R., Kraus, S., Wölfl, M., Eder, M., Bertrand, H., … Chen, Y.-B. (2023). Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Advances, 7(16), 4479–4491. https://doi.org/10.1182/bloodadvances.2023009885

Thakar, M. S., Logan, B. R., Puck, J. M., Dunn, E. A., Buckley, R. H., Cowan, M. J., O’Reilly, R. J., Kapoor, N., Satter, L. F., Pai, S.-Y., Heimall, J., Chandra, S., Ebens, C. L., Chellapandian, D., Williams, O., Burroughs, L. M., Saldana, B. D., Rayes, A., Madden, L. M., … Notarangelo, L. D. (2023). Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. The Lancet, 402(10396), 129–140. https://doi.org/10.1016/s0140-6736(23)00731-6

Murthy, G. S. G., Kim, S., Estrada-Merly, N., Abid, M. B., Aljurf, M., Assal, A., Badar, T., Badawy, S. M., Ballen, K., Beitinjaneh, A., Cerny, J., Chhabra, S., DeFilipp, Z., Dholaria, B., Perez, M. A. D., Farhan, S., Freytes, C. O., Gale, R. P., Ganguly, S., … Saber, W. (2023). Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica, 108(7), 1900–1908. https://doi.org/10.3324/haematol.2022.281958

Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., Shaffer, B. C., El Jurdi, N., Loren, A. W., Solh, M., Hall, A. C., Alousi, A. M., Jamy, O. H., Perales, M.-A., Yao, J. M., … Holtan, S. G. (2023). Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. New England Journal of Medicine, 388(25), 2338–2348. https://doi.org/10.1056/nejmoa2215943

Kinoshita, H., Mandava, M., Jensen-Wachspress, M., Lang, H., Joy, E., Tanna, J., McCann, C. D., O’Brien, S., Burnett, S., Shibli, A., Hoq, F., Bhatia, M., Hanley, P. J., Dávila Saldaña, B., Mahadeo, K. M., Bollard, C. M., Keller, M. D., & Abraham, A. (2023). Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease. Blood Advances, 7(10), 2105–2116. https://doi.org/10.1182/bloodadvances.2022008219

Sembill, S., Ampatzidou, M., Chaudhury, S., Dworzak, M., Kalwak, K., Karow, A., Kiani, A., Krumbholz, M., Luesink, M., Naumann-Bartsch, N., De Moerloose, B., Osborn, M., Schultz, K. R., Sedlacek, P., Giona, F., Zwaan, C. M., Shimada, H., Versluijs, B., Millot, F., … Metzler, M. (2023). Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia, 37(3), 505–517. https://doi.org/10.1038/s41375-023-01822-2

Etra, A., Capellini, A., Alousi, A., Al Malki, M. M., Choe, H., DeFilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., … Levine, J. E. (2023). Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood, 141(5), 481–489. https://doi.org/10.1182/blood.2022017442

Patel, C., Pasciolla, M., Abramova, R., Salerno, D., Gomez-Arteaga, A., Shore, T. B., Orfali, N., Mayer, S., Hsu, J., Phillips, A. A., Chaekal, O.-K., Satlin, M. J., Soave, R., Kodiyanplakkal, R. P. L., Drelick, A., Plate, M., & Besien, K. V. (2023). Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients. Transplantation and Cellular Therapy, 29(2), 132.e1-132.e5. https://doi.org/10.1016/j.jtct.2022.10.023

Stenger, E., Xiang, Y., Wetzel, M., Gillespie, S., Chellapandian, D., Shah, R., Arnold, S. D., Bhatia, M., Chaudhury, S., Eckrich, M. J., Kanter, J., Kasow, K. A., Krajewski, J., Nickel, R. S., Ngwube, A. I., Olson, T. S., Rangarajan, H. G., Wobma, H., Guilcher, G. M. T., … Abraham, A. (2023). Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance. Transplantation and Cellular Therapy, 29(1), 47.e1-47.e10. https://doi.org/10.1016/j.jtct.2022.10.012

Etra, A., Gergoudis, S., Morales, G., Spyrou, N., Shah, J., Kowalyk, S., Ayuk, F., Baez, J., Chanswangphuwana, C., Chen, Y.-B., Choe, H., DeFilipp, Z., Gandhi, I., Hexner, E., Hogan, W. J., Holler, E., Kapoor, U., Kitko, C. L., Kraus, S., … Levine, J. E. (2022). Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Advances, 6(12), 3707–3715. https://doi.org/10.1182/bloodadvances.2022007296

Nosotti, M., Leiva-Juarez, M., D’Ovidio, F., Van Raemdonck, D., Ceulemans, L., Keshavjee, S., Rackauskas, M., Paladini, P., Luzzi, L., Casado, P. M., Alvarez, A., Inci, I., Ehrsam, J., Krueger, T., Roth, A., Rea, F., Schiavon, M., & Rosso, L. (2022). Survival After Lung Transplantation for Chronic Hypersensitivity Pneumonitis: Results From a Large International Cohort Study. Transplant International, 35. https://doi.org/10.3389/ti.2022.10450

Merola, J., Shamim, A., & Weiner, J. (2022). Update on immunosuppressive strategies in intestinal transplantation. Current Opinion in Organ Transplantation, 27(2), 119–125. https://doi.org/10.1097/mot.0000000000000958

Wu, Y., Fu, J., Wang, H., & Yu, X.-Z. (2021). Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.778996

Smith, S. M., Zhang, S., Sundaram, V., Roth, M., Andolina, J. R., Schapira, L., Sakamoto, K. M., Kolb, E. A., Hijiya, N., & Chaudhury, S. (2021). Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML. Pediatric Hematology and Oncology, 39(5), 453–467. https://doi.org/10.1080/08880018.2021.2017085